Chondroitin Sulfate + Glucosamine

Verify with FDA CVM →

18 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
2
Deaths Reported
1110.0%
Death Rate

Active Ingredients

Chondroitin SulfateChondroitin Sulfate + GlucosamineGlucosamine

Administration Routes

UnknownOral

Species Affected

Dog 17
Cat 1

Most Affected Breeds

Beagle 2
Boxer (German Boxer) 2
Retriever - Labrador 2
Dog (unknown) 2
Shepherd Dog - German 1
Sheepdog - Polish Lowland 1
Crossbred Canine/dog 1
Cat (unknown) 1
Sheepdog - Long-haired Pyrenean 1
Siberian Husky 1

Most Reported Reactions

Vomiting 5
Diarrhoea 4
Behavioural disorder NOS 3
Not eating 2
Drinking a lot 2
Decreased appetite 2
Lethargy (see also Central nervous system depression in Neurological) 2
Muscle spasm NOS 2
Tremor 2
Bruising 2
Central nervous system disorder NOS 2
Urinary tract infection 1

Outcome Breakdown

Outcome Unknown
6 (33.3%)
Recovered/Normal
5 (27.8%)
Ongoing
5 (27.8%)
Euthanized
1 (5.6%)
Died
1 (5.6%)

Data Summary

Metric Value
Total adverse event reports 18
Reports involving death 2
Case-fatality rate (reported events) 1110.0%
Distinct species in reports 2
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Chondroitin Sulfate + Glucosamine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 18 adverse event reports referencing Chondroitin Sulfate + Glucosamine, including 2 reports in which the animal died — a 1110.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Chondroitin Sulfate, Chondroitin Sulfate + Glucosamine, Glucosamine. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Chondroitin Sulfate + Glucosamine reports are Dog (17 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Beagle (2), Boxer (German Boxer) (2), Retriever - Labrador (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Chondroitin Sulfate + Glucosamine are Vomiting (5), Diarrhoea (4), Behavioural disorder NOS (3), Not eating (2). Of the 18 reports with a coded outcome, Outcome Unknown is the leading category at 33.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Chondroitin Sulfate + Glucosamine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial